Edwards Lifesciences Corporation (NYSE:EW) VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $112.58, for a total transaction of $2,134,516.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Larry L. Wood also recently made the following trade(s):

  • On Wednesday, August 30th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $111.81, for a total transaction of $2,119,917.60.

Edwards Lifesciences Corporation (NYSE EW) traded down 0.71% during midday trading on Monday, reaching $112.69. 984,040 shares of the company traded hands. The firm has a market capitalization of $23.80 billion, a price-to-earnings ratio of 34.18 and a beta of 0.64. The firm’s 50 day moving average price is $113.99 and its 200 day moving average price is $108.88. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. During the same period in the previous year, the firm posted $0.76 earnings per share. The company’s revenue was up 10.9% on a year-over-year basis. On average, analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/18/insider-selling-edwards-lifesciences-corporation-ew-vp-sells-18960-shares-of-stock.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Sabal Trust CO raised its stake in shares of Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after acquiring an additional 14 shares during the last quarter. Alps Advisors Inc. raised its stake in shares of Edwards Lifesciences Corporation by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after acquiring an additional 14 shares during the last quarter. Alexandria Capital LLC raised its stake in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after acquiring an additional 19 shares during the last quarter. M Holdings Securities Inc. raised its stake in shares of Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock worth $389,000 after acquiring an additional 62 shares during the last quarter. Finally, Veritable L.P. raised its stake in shares of Edwards Lifesciences Corporation by 1.2% in the second quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock worth $738,000 after acquiring an additional 71 shares during the last quarter. 82.08% of the stock is owned by institutional investors.

A number of brokerages recently weighed in on EW. BidaskClub raised shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 22nd. Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 price target on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, June 8th. Jefferies Group LLC reaffirmed a “buy” rating and set a $115.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, June 30th. Finally, SunTrust Banks, Inc. upped their price target on shares of Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research report on Monday, July 17th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $120.75.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.